AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Acyl-coenzyme A diphosphatase NUDT19

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

A8MXV4

UPID:

NUD19_HUMAN

Alternative names:

Nucleoside diphosphate-linked moiety X motif 19

Alternative UPACC:

A8MXV4

Background:

Acyl-coenzyme A diphosphatase NUDT19, alternatively known as Nucleoside diphosphate-linked moiety X motif 19, plays a crucial role in lipid metabolism. It specifically hydrolyzes fatty acyl-CoA, converting it into acyl-4'-phosphopantetheine and adenosine 3',5'-bisphosphate. This enzyme exhibits a preference for medium-chain acyl-CoA esters and shows higher activity with unsaturated over saturated esters. Additionally, NUDT19 has been identified to possess decapping activity towards dpCoA-capped RNAs in vitro.

Therapeutic significance:

Understanding the role of Acyl-coenzyme A diphosphatase NUDT19 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.